

June 24, 2015

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (cd-119)

VOLIXIBAT POTASSIUM

PRONUNCIATION

voe lix' i bat


THERAPEUTIC CLAIM

Treatment of gastrointestinal, metabolic and liver disease

CHEMICAL NAMES

1. Urea, *N*-[3-[(3*S*,4*R*,5*R*)-3-butyl-7-(dimethylamino)-3-ethyl-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenyl]-*N*-[3-*O*-(phenylmethyl)-6-*O*-sulfo-β-*D*-glucopyranosyl]-, potassium salt (1:1)
2. *N*-(3-*O*-benzyl-6-*O*-sulfo-β-*D*-glucopyranosyl)-*N*-{3-[(3*S*,4*R*,5*R*)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1*H*-1λ⁶-benzothiepin-5-yl]phenyl}urea potassium salt

STRUCTURAL FORMULA



MOLECULAR FORMULA

 $C_{38}H_{50}KN_3O_{12}S_2$

MOLECULAR WEIGHT

844.0

TRADEMARK

None as yet

SPONSOR

Shire Human Genetic Therapies, Inc.

CODE DESIGNATIONS

LUM002

CAS REGISTRY NUMBER

1431935-92-0

UNII

YWU8J6O8J0

gbk